What's Happening With These Biotech Stocks? -- Opko Health, Kura Oncology, PDL BioPharma, and Progenics Pharma

NEW YORK, Dec. 07, 2017 /PRNewswire/ --In keeping with the commitment to dynamically provide members with timely information, WallStEquities.com has issued free tailored Stock Review on OPK, KURA, PDLI, and PGNX which is a click away at www.wallstequities.com/registration. Research reports have been issued by WallStEquities.com on Opko Health Inc. (NASDAQ: OPK), Kura Oncology Inc. (NASDAQ: KURA), PDL BioPharma Inc. (NASDAQ: PDLI), and Progenics Pharmaceuticals Inc. (NASDAQ: PGNX). These companies operate in the Biotech space, which is mainly involved in developing new drug treatments, tests, and other medical technologies. The sector is notoriously volatile, in large part, because investors are often banking on a firm's latest drug or treatment receiving regulatory approval, where the chances of success are low. See what Wall St. Equities' research desk has to say about these stocks, join our members and enjoy of your free research reports at:

www.wallstequities.com/registration

Opko Health

On Wednesday, shares in Miami, Florida headquartered Opko Health Inc. saw a slight drop of 0.99%, ending the day at $4.99. The stock recorded a trading volume of 3.45 million shares. The Company's shares are trading below their 50-day moving average by 19.06%. Moreover, shares of Opko Health, which engages in the diagnostics and pharmaceuticals business in the US, Ireland, Chile, Spain, Israel, and Mexico, have a Relative Strength Index (RSI) of 35.98.  

On November 27^th, 2017, Opko Health announced that it has enrolled the first patient in a Phase-2b dose ranging trial of OPK88004, its orally administered selective androgen receptor modulator, to treat men with benign prostatic hypertrophy (BPH) or enlarged prostate. The trial will enroll approximately 125 men with BPH at 30 sites in the US to identify appropriate doses given over a four-month treatment period to reduce prostate size, the primary efficacy endpoint of the study. Looking for insightful coverage on OPK sign up for free at:

www.wallstequities.com/registration/?symbol=OPK

Kura Oncology

Shares in La Jolla, California headquartered Kura Oncology Inc. ended the day 0.35% lower at $14.15 with a total trading volume of 197,114 shares. In the previous three months and since the start of this year, the stock has surged 106.57% and 139.83%, respectively. The Company's shares are trading above their 200-day moving average by 35.80%. Furthermore, shares of Kura Oncology, which develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer, have an RSI of 39.76. Today's complimentary research report on KURA is accessible at:

www.wallstequities.com/registration/?symbol=KURA

PDL BioPharma

At the close of trading on Wednesday, shares in Incline Village, Nevada headquartered PDL BioPharma Inc. finished flat at $2.93 with a total trading volume of 791,912 shares. The stock has advanced 38.21% on an YTD basis. The Company's shares are trading above their 200-day moving average by 11.76%. Additionally, shares of PDL BioPharma, which acquires and manages companies, products, royalty agreements, and debt facilities in the biotech, pharmaceutical, and medical device industries in the US, Europe, and internationally, have an RSI of 45.86. 

On November 15^th, 2017, Noden Pharma DAC, a wholly-owned subsidiary of PDL BioPharma, announced the approval by the US FDA of Tekturna® (aliskiren) Oral Pellets for the treatment of hypertension in adults and children six years of age and older. The new formulation and pediatric indication were approved through the FDA priority review process. Register now for your free research document on PDLI at:

www.wallstequities.com/registration/?symbol=PDLI

Progenics Pharmaceuticals

New York-based Progenics Pharmaceuticals Inc.'s shares recorded a trading volume of 647,618 shares at the end of yesterday's session. The stock closed the day 0.18% higher at $5.55. The Company's shares are trading below their 50-day moving average by 11.06%. Additionally, shares of Progenics Pharma, which develops medicines and other technologies to target and treat cancer in the US and internationally, have an RSI of 41.59.  Click on the link below and see our free report PGNX at:

www.wallstequities.com/registration/?symbol=PGNX

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

WSE has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: [email protected]
Phone number: +21-32-044-483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Wall St. Equities

Related Links

http://www.wallstequities.com